TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04499846

Intervention type: OTHER
Intervention: Therapeutic education
Description: Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
Study: NCT00961441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days
Study: NCT03617913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study: NCT00820144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of CTB by sublingual way
Description: absorption of CTB by sublingual way
Study: NCT03617913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT01143714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Petrolatum
Description: Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
Study: NCT01767181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive light therapy
Description: Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
Study: NCT01350050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: articaine
Description: Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 9% Sodium Chloride solution for injection
Description: 9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
Study: NCT01767181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
Study: NCT01807949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet
Study: NCT02972957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasovac-S
Description: one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasovac-S
Description: one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasovac-S
Description: one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
Study: NCT02474823

Intervention type: OTHER
Group type: OTHER
Intervention: polysomnogram
Description: all participants will undergo PSG for assessment of OSA

Intervention type: OTHER
Group type: OTHER
Intervention: home sleep test
Description: all participants will undergo HST for assessment of OSA

Intervention type: OTHER
Group type: OTHER
Intervention: Easy Sleep Apnea Predictor
Description: all participants will undergo ESAP for assessment of OSA
Study: NCT04083118

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI
Description: Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI
Description: Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta

Intervention type: DIAGNOSTIC_TEST
Intervention: Repeat 18F sodium fluoride PET/MRI
Description: as per first study visit but without the PET/CT
Study: NCT00147992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants in totally edentate upper and lower jaw
Description: Immediate loading of implants in totally edentate upper and lower jaw.
Study: NCT01061320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha tocopherol
Description: The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
Study: NCT00161616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: InductOs
Description: InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage

Intervention type: DRUG
Group type: OTHER
Intervention: InductOs
Description: InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
Study: NCT01247454

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: academic detailing
Description: EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) prompt
Description: EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR prompt and patient prompt
Description: EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
Study: NCT03036852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
Study: NCT01820806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg dose of [14C] GLPG0634
Description: Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
Study: NCT02611102

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MCT oil + Butter in Coffee
Description: 2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT oil + Butter in Coffee
Description: 2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
Study: NCT00977483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioctic Acid
Description: 600mg tablet once daily 4 years double-blind treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet once daily 4 years double-blind treatment period
Study: NCT01739894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP Paclitaxel
Description: Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
Study: NCT02563730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung biopsy
Description: transbronchial lung biopsy. First kryobiopsy, second open biopsy
Study: NCT06030219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: 10-day course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Pill
Description: 10-day course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 10-day course
Study: NCT03130218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint oil aromatherapy
Description: Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
Study: NCT05610592

Intervention type: PROCEDURE
Intervention: total mesorectal exicision
Study: NCT02387983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole 300 mg solid oral tablet
Study: NCT01527136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entolimod
Description: Given IM or SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04402775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: A tourniquet will be used during surgery
Study: NCT00877604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tauroursodeoxycholic acid (TUDCA)
Description: Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
Study: NCT03214874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Demadex 20mg Tablet
Description: Immediate Release (IR) Torsemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER Torsemide 20mg Tablet
Description: Extended Release Torsemide 20 mg tablet given once daily
Study: NCT02583893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT02833545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone gas
Description: Injection of ozone gas intra articularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection
Description: Injection of steroids (diprospan) intra articularly
Study: NCT02426853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photos
Description: At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlets
Description: At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlets
Description: At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
Study: NCT02293330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous infusion of levobupivacaine
Description: continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent bolus infusion of levobupivacaine
Description: Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
Study: NCT00821873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CR Plug
Description: CR Plug will be placed in the harvest site
Study: NCT04008966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined oral contaraceptive pills
Description: 1 tablet daily between days 5 and 25 of the cycle before stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined oral contaraceptive pills
Description: 1 tablet daily between days 5 and 25 of the cycle before stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: 300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: 300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
Study: NCT00877604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo by oral route at the same dosing schedule
Study: NCT04008966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinaru gonadotropin
Description: 150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinaru gonadotropin
Description: 150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: 0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: 0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: 0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 hours after triggering under the guidance of transvaginal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 hours after triggering under the guidance of transvaginal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural Progesterone
Description: 400 mg twice daily per vagina

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural Progesterone
Description: 400 mg twice daily per vagina
Study: NCT02074592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self assessment of ultrasound fetal biometry images
Description: self assessment of ultrasound fetal biometry images followed by automatically generated feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assessment of ultrasound fetal biometry images by expert
Description: assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
Study: NCT02533375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study: NCT00076804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy
Description: Use of a patient nominated peer supporter who will observe the morning dose of ARVs
Study: NCT03150849

Intervention type: DIAGNOSTIC_TEST
Intervention: C-X-C Chemokine Receptor 4
Description: marker assessed by flowcytometry in a blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: C-X-C Chemokine Receptor 4
Description: marker assessed by flowcytometry in a blood sample
Study: NCT03039660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RefreshMD
Description: Online Sleep Improvement Course

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bond Between Us
Description: Online Educational Course
Study: NCT03842579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Supervised progressive explosive type heavy-resistance training two times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: Daily supplementation with milk-based protein-rich products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-protein diet
Description: Daily supplementation with milk-based protein-rich products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recommendations
Description: Provided with the official national recommendations on nutrition
Study: NCT04161846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Training
Description: The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Person Training
Description: The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
Study: NCT03323853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Assessment and Referral System (CARS) Self-Assessment Screener
Description: Subjects will take the CARS-SA Screener.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Assessment and Referral System (CARS) Self-Assessment Screener
Description: Subjects will take the CARS-SA Screener.
Study: NCT01713049

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FLT
Description: 0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).